Won 2007.

Methods	Design: open‐label, randomised study
Participants	Number of participants randomised: 72 Sex: 50% male Mean age: 45.8 years (range 17‐70) Number included in analysis: 49 Number completing treatment: assumed 49 (no discontinuations reported) Inclusion criteria: unclear Type/location/characteristics of infection: distal or distolateral subungual toenail onychomycosis, not more than 75% involvement of nail plate, confirmed by microscopy or culture Duration of infection: not specified Exclusion criteria: any systemic disease Washout period: 1 month for topical antifungal therapies or topical steroids, 2 months for systemic antifungal therapy Setting: 2 research centres in Seoul, Korea Comorbidities: not stated
Interventions	Itraconazole (400 mg/d) for 1 week in every 4 of 12 weeks Terbinafine (250 mg/d) for 12 weeks
Outcomes	Duration of follow‐up: 96 weeks Outcomes measured: mycological cure, clinical cure, adverse events, subject acceptance Safety and tolerability: adverse events reporting, measurement of alanine aminotransferase, aspartate aminotransferase and gamma‐glutamyl transpeptidase
Source of funding	No information available
Conflict of interest	No conflict of interest identified
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "[p]articipants were randomly selected" to their treatment group Comment: no method is given
Allocation concealment (selection bias)	Unclear risk	Quote: "[p]articipants were randomly selected" to their treatment group Comment: method not stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: blinding is not mentioned in this study, and participants were given 300 mg of itraconazole daily for 1 week every 4 weeks or 250 mg terbinafine daily for 12 weeks. Because of these factors, it is possible that blinding could have been broken.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: blinding is not mentioned in this study
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: because the nail involvement was statistically different between groups, 21 of the initial 70 randomised participants were excluded, and the outcome data are unavailable. No systemic differences between withdrawals between groups
Selective reporting (reporting bias)	Low risk	All results presented as set out in the Methods. All prespecified outcomes appear to be reported.
Other bias	Low risk	No other risks of bias identified

AE: adverse event; ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate transaminase; CBC: complete blood count; ECG: electrocardiogram; GGT: gammaglutamyl transferase; GI: gastrointestinal; IIT: itraconazole‐itraconazole‐terbinafine (3 pulses total); ITT: intention‐to‐treat; KOH: potassium hydroxide; LFT: liver function test; NA: not applicable;RCT: randomised controlled trial; RFT: renal function test; TRIPA: trichophytin antigen; TTT: terbinafine × 3 pulses.